Institution · Institut Gustave Roussy
Most cited papers from Institut Gustave Roussy
Institut Gustave Roussy
What are the most cited papers from Institut Gustave Roussy?
The most cited paper from Institut Gustave Roussy is "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer" (Bryan R. Haugen, Erik Karl Alexander, Keith Christopher Bible et al., 2015), with 16,719 citations. Next come "The Hallmarks of Aging" (15,388) and "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" (15,337).
Showing 50 of 60 papers. Every paper with more than 3,006 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Bryan R. Haugen, Erik Karl Alexander, Keith Christopher Bible et al. · Thyroid | 14 Oct 2015 | 16,719 |
| 2 | The Hallmarks of Aging Carlos López-Otı́n, Marı́a A. Blasco, Linda Partridge et al. · Cell | Jun 2013 | 15,388 |
| 3 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Frank Stephen Hodi et al. · New England Journal of Medicine | 5 Jun 2010 | 15,337 |
| 4 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine | 11 May 2011 | 7,927 |
| 5 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine | 5 Jun 2011 | 7,801 |
| 6 | Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine | 13 May 2020 | 7,547 |
| 7 | Autophagy in the Pathogenesis of Disease Beth Levine, Guido Kroemer · Cell | 2008 | 7,137 |
| 8 | Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer David S. Cooper, Gerard M. Doherty, Bryan R. Haugen et al. · Thyroid | 27 Oct 2009 | 6,774 |
| 9 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 Lorenzo Galluzzi et al. · Cell Death and Differentiation | 23 Jan 2018 | 6,760 |
| 10 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh et al. · Nature | 25 Nov 2014 | 6,760 |
| 11 | Hallmarks of aging: An expanding universe Carlos López-Otı́n, Marı́a A. Blasco, Linda Partridge et al. · Cell | 2023 | 6,477 |
| 12 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon et al. · New England Journal of Medicine | 19 Apr 2015 | 6,312 |
| 13 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy | 2 Jan 2016 | 6,023 |
| 14 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine | 25 Sep 2015 | 5,972 |
| 15 | Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer Ian F. Tannock, Ronald de Wit, William R. Berry et al. · New England Journal of Medicine | 6 Oct 2004 | 5,779 |
| 16 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Sanjeev Mariathasan et al. · Nature | Feb 2018 | 5,718 |
| 17 | Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Bertrand Routy et al. · Science | 2 Nov 2017 | 5,679 |
| 18 | Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine | 18 Nov 2017 | 5,475 |
| 19 | Exosomes: composition, biogenesis and function Clotilde Théry, Laurence Zitvogel, Sebastián Amigorena · Nature reviews. Immunology | Aug 2002 | 5,446 |
| 20 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 5,431 |
| 21 | The consensus molecular subtypes of colorectal cancer Justin Guinney et al. · Nature Medicine | 12 Oct 2015 | 5,415 |
| 22 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst et al. · Nature | 25 Nov 2014 | 5,353 |
| 23 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert Louis Ferris et al. · New England Journal of Medicine | 9 Oct 2016 | 5,189 |
| 24 | Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Vancheswaran Gopalakrishnan et al. · Science | 2 Nov 2017 | 4,849 |
| 25 | Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine | 10 Jan 2007 | 4,813 |
| 26 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine | 21 Mar 2018 | 4,756 |
| 27 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine | 15 Aug 2012 | 4,645 |
| 28 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert et al. · New England Journal of Medicine | 5 Jun 2011 | 4,523 |
| 29 | Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann Sebastian De Bono et al. · New England Journal of Medicine | 25 May 2011 | 4,448 |
| 30 | Ferroptosis: molecular mechanisms and health implications Daolin Tang, Xin Chen, Rui Kang et al. · Cell Research | 2 Dec 2020 | 4,365 |
| 31 | Bayesian image restoration, with two applications in spatial statistics Julian E. Besag, Jeremy C. York, Annie Molli� · Annals of the Institute of Statistical Mathematics | Mar 1991 | 4,337 |
| 32 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Joseph David Khoury et al. · Leukemia | 22 Jun 2022 | 4,204 |
| 33 | Guidelines for the use and interpretation of assays for monitoring autophagy Daniel J. Klionsky et al. · Autophagy | Apr 2012 | 4,068 |
| 34 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Rita Alaggio et al. · Leukemia | 22 Jun 2022 | 4,010 |
| 35 | The repertoire of mutational signatures in human cancer Ludmil B. Alexandrov et al. · Nature | 5 Feb 2020 | 3,854 |
| 36 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg et al. · The Lancet | 5 Mar 2016 | 3,762 |
| 37 | Self-eating and self-killing: crosstalk between autophagy and apoptosis Maria Chiara Maiuri, Einat Zalckvar, Adi Kimchi et al. · Nature Reviews Molecular Cell Biology | 23 Aug 2007 | 3,659 |
| 38 | Mitochondrial Membrane Permeabilization in Cell Death Guido Kroemer, Lorenzo Galluzzi, Catherine Brenner · Physiological Reviews | 2007 | 3,622 |
| 39 | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature | 27 Mar 2005 | 3,573 |
| 40 | Autophagy and the Integrated Stress Response Guido Kroemer, Guillermo Mariño, Beth Levine · Molecular Cell | Oct 2010 | 3,556 |
| 41 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Eric Van Cutsem et al. · Annals of Oncology | 5 Jul 2016 | 3,512 |
| 42 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Marie Vétizou et al. · Science | 5 Nov 2015 | 3,498 |
| 43 | Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine | Jun 2013 | 3,429 |
| 44 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid et al. · New England Journal of Medicine | 2 Jun 2013 | 3,425 |
| 45 | The Pathophysiology of Mitochondrial Cell Death Douglas R. Green, Guido Kroemer · Science | 30 Jul 2004 | 3,411 |
| 46 | Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 Guido Kroemer et al. · Cell Death and Differentiation | 10 Oct 2008 | 3,386 |
| 47 | Pan-cancer analysis of whole genomes Lauri A. Aaltonen et al. · Nature | 5 Feb 2020 | 3,360 |
| 48 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine | 4 Jun 2017 | 3,322 |
| 49 | Immunogenic Cell Death in Cancer Therapy Guido Kroemer, Lorenzo Galluzzi, Oliver Kepp et al. · Annual Review of Immunology | 16 Nov 2012 | 3,313 |
| 50 | Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer Jacques Bernier, Christian Domenge, Mahmut Özsahin et al. · New England Journal of Medicine | 5 May 2004 | 3,214 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.